322 related articles for article (PubMed ID: 33256276)
21. Evaluation methods for pretransplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinoma.
Shindoh J; Sugawara Y; Nagata R; Kaneko J; Tamura S; Aoki T; Sakamoto Y; Hasegawa K; Tanaka T; Kokudo N
Transpl Int; 2014 Apr; 27(4):391-8. PubMed ID: 24472068
[TBL] [Abstract][Full Text] [Related]
22. Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinoma.
Wang CS; Lin CL; Lee HC; Chen KY; Chiang MF; Chen HS; Lin TJ; Liao LY
World J Gastroenterol; 2005 Oct; 11(39):6115-9. PubMed ID: 16273636
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of Tumor Response Using Alpha-fetoprotein and Des-gamma-carboxy Prothrombin in Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization.
Cerban R; Ester C; Iacob S; Paslaru L; Dumitru R; Grasu M; Constantin G; Popescu I; Gheorghe L
Chirurgia (Bucur); 2018; 113(4):524-533. PubMed ID: 30183583
[TBL] [Abstract][Full Text] [Related]
24. Clinical Significance of Preoperative Hepatocellular Carcinoma With High
Yamao T; Yamashita YI; Imai K; Umezaki N; Tsukamoto M; Kitano Y; Arima K; Miyata T; Nakagawa S; Okabe H; Hayashi H; Chikamoto A; Ishiko T; Baba H
Anticancer Res; 2019 Feb; 39(2):883-889. PubMed ID: 30711971
[TBL] [Abstract][Full Text] [Related]
25. Clinical utility of simultaneous measurement of alpha-fetoprotein and des-γ-carboxy prothrombin for diagnosis of patients with hepatocellular carcinoma in China: A multi-center case-controlled study of 1,153 subjects.
Song P; Feng X; Inagaki Y; Song T; Zhang K; Wang Z; Zheng S; Ma K; Li Q; Kong D; Wu Q; Zhang T; Zhao X; Hasegawa K; Sugawara Y; Kokudo N; Tang W;
Biosci Trends; 2014 Oct; 8(5):266-73. PubMed ID: 25382443
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic Value of Serum Biomarkers for Patients Undergoing Curative Resection with Non-B, Non-C Hepatocellular Carcinoma.
Li Y; Chen Y; Chen J
J Coll Physicians Surg Pak; 2020 Feb; 30(2):134-138. PubMed ID: 32036818
[TBL] [Abstract][Full Text] [Related]
27. Positive status of alpha-fetoprotein and des-gamma-carboxy prothrombin: important prognostic factor for recurrent hepatocellular carcinoma.
Kaibori M; Matsui Y; Yanagida H; Yokoigawa N; Kwon AH; Kamiyama Y
World J Surg; 2004 Jul; 28(7):702-7. PubMed ID: 15185000
[TBL] [Abstract][Full Text] [Related]
28. Prognostic and diagnostic value of des-γ-carboxy prothrombin in liver cancer.
Bertino G; Ardiri AM; Calvagno GS; Bertino N; Boemi PM
Drug News Perspect; 2010 Oct; 23(8):498-508. PubMed ID: 21031166
[TBL] [Abstract][Full Text] [Related]
29. Des-gamma-carboxy prothrombin and alpha-fetoprotein positive status as a new prognostic indicator after hepatic resection for hepatocellular carcinoma.
Shimada M; Takenaka K; Fujiwara Y; Gion T; Kajiyama K; Maeda T; Shirabe K; Sugimachi K
Cancer; 1996 Nov; 78(10):2094-100. PubMed ID: 8918402
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic Role of Blood Tumor Markers in Predicting Hepatocellular Carcinoma in Liver Cirrhosis Patients Undergoing Liver Transplantation.
Kim Y; Park YH; Hwang S; Kim KH; Ahn CS; Moon DB; Ha TY; Song GW; Jung DH; Park GC; Lee SG
Ann Transplant; 2016 Oct; 21():660-667. PubMed ID: 27777395
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study.
Ji J; Wang H; Li Y; Zheng L; Yin Y; Zou Z; Zhou F; Zhou W; Shen F; Gao C
PLoS One; 2016; 11(4):e0153227. PubMed ID: 27070780
[TBL] [Abstract][Full Text] [Related]
32. The Half-Life of Serum Des-Gamma-Carboxy Prothrombin Is a Prognostic Index of Survival and Recurrence After Liver Resection for Hepatocellular Carcinoma.
Okamura Y; Sugiura T; Ito T; Yamamoto Y; Ashida R; Uesaka K
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):921-928. PubMed ID: 27638677
[TBL] [Abstract][Full Text] [Related]
33. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size.
Nakamura S; Nouso K; Sakaguchi K; Ito YM; Ohashi Y; Kobayashi Y; Toshikuni N; Tanaka H; Miyake Y; Matsumoto E; Shiratori Y
Am J Gastroenterol; 2006 Sep; 101(9):2038-43. PubMed ID: 16848811
[TBL] [Abstract][Full Text] [Related]
34. Next-generation des-r-carboxy prothrombin for immunohistochemical assessment of vascular invasion by hepatocellular carcinoma.
Yamazaki S; Takayama T; Kurokawa T; Shimamoto N; Mitsuka Y; Yoshida N; Higaki T; Sugitani M
BMC Surg; 2020 Sep; 20(1):201. PubMed ID: 32928172
[TBL] [Abstract][Full Text] [Related]
35. [Diagnostic Value of Abnormal Prothrombin in HBV-related AFP-negative Hepatocellular Carcinoma].
Wei RR; Wang CC; Li DJ; Hu XY; Liu K
Sichuan Da Xue Xue Bao Yi Xue Ban; 2020 May; 51(3):411-415. PubMed ID: 32543152
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of anatomical resection and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma.
Imamura H; Matsuyama Y; Miyagawa Y; Ishida K; Shimada R; Miyagawa S; Makuuchi M; Kawasaki S
Br J Surg; 1999 Aug; 86(8):1032-8. PubMed ID: 10460639
[TBL] [Abstract][Full Text] [Related]
37. Prediction of vascular invasion in hepatocellular carcinoma by next-generation des-r-carboxy prothrombin.
Kurokawa T; Yamazaki S; Mitsuka Y; Moriguchi M; Sugitani M; Takayama T
Br J Cancer; 2016 Jan; 114(1):53-8. PubMed ID: 26679378
[TBL] [Abstract][Full Text] [Related]
38. Different Characteristics of Serum Alfa Fetoprotein and Serum Des-gamma-carboxy Prothrombin in Resected Hepatocellular Carcinoma.
Hayashi M; Yamada S; Takano N; Okamura Y; Takami H; Inokawa Y; Sonohara F; Tanaka N; Shimizu D; Hattori N; Kanda M; Tanaka C; Nakayama G; Koike M; Kodera Y
In Vivo; 2021; 35(3):1749-1760. PubMed ID: 33910859
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Yamamoto M; Takasaki K; Nakano M
J Gastroenterol Hepatol; 2002 Jul; 17(7):772-8. PubMed ID: 12121507
[TBL] [Abstract][Full Text] [Related]
40. A Clinical Scoring System for Predicting Microvascular Invasion in Patients with Hepatocellular Carcinoma Within the Milan Criteria.
Ryu T; Takami Y; Wada Y; Tateishi M; Hara T; Yoshitomi M; Momosaki S; Yasumori K; Saitsu H; Okuda K
J Gastrointest Surg; 2019 Apr; 23(4):779-787. PubMed ID: 30788712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
